KRAS and adenocarcinoma: However, Miller et al (2006) showed that in their study of adenocarcinoma with bronchioloalveolar cell feature treated with erlotinib, some of the tumours with KRAS mutations showed minor tumour shrinkage, although response rate of lung cancer with KRAS mutations was zero by RECIST.